“OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s82. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/86.